

ASX Announcement
27 February 2025 (Melbourne, Australia)
Optiscan Imaging Ltd (ASX:OIL)

Optiscan Half Year Report
Period Ending 31 December 2024

Optiscan Imaging Limited (ASX:OIL) ('Optiscan' or the 'Company'), a global leader in the development, manufacturing, and commercialisation of imaging technologies for medical, translational and pre-clinical applications, is pleased to announce its financial report and business update for the six months ending 31st December 2024 (the half-year). All financial results are in Australian dollars.

Highlights for the Half-Year

- Completed the design, development and build of Optiscan's dedicated pathology device, with the Company's InForm™ device revealed subsequent to the end of the half-year.
- Commenced the development of a dedicated veterinary imaging product.
- Successful Advance Overseas Finding Application with the Australian Government, resulting in an additional \$1 million R&D tax refund.
- Successful sales of ViewnVivo® achieved in China and increased business development activities in the US and Europe.
- Collaboration agreement signed with the University of Minnesota College of Veterinary Medicine to begin research for the veterinary market.
- Manufacture of several InVue™ imaging devices for testing and clinical studies to be undertaken at the Royal Melbourne Hospital and Mayo Clinic.

Optiscan's Chief Executive Officer and Managing Director, Dr. Camile Farah commented:

"Optiscan has made significant strides on multiple fronts over its latest half-year reporting period. It saw the Company do so much more than just strengthen our financial position. The period also saw a continued expansion of our product portfolio, the inking of new strategic collaboration agreements that grew the potential addressable markets for our evolving portfolio, further advances in regulatory requirements, and increased business development activities in Europe and the US. As we continue to evolve and expand, each strategic milestone delivered builds on the value inherent in our product portfolio and positions us for long-term success."

– ends –

This announcement has been authorised for release by the Board of Optiscan.

For further information, please contact:

Shareholder & General Enquiries

Optiscan Imaging Ltd

Dr Camile Farah

T: +61 3 9538 3333

E: ceo@optiscan.com

Media & Investor Enquiries

The Capital Network

Julia Maguire

T: +61 2 7257 7338

E: julia@thecapitalnetwork.com.au

About Optiscan

Optiscan Imaging Ltd (ASX: OIL) is a global leader in the development, manufacturing, and commercialisation of confocal endomicroscopic imaging technologies for medical, translational and pre-clinical applications. Our technology enables real-time, non-destructive, 3D, *in-vivo* digital imaging at the single-cell level.

We are driven by developing technology and its use to give healthcare providers and researchers the highest quality real-time microscopic imaging tools to enable the early detection and management of disease, improve patient outcomes, and reduce the high cost of curative medicine and associated procedures.

Our patent-protected proprietary technology, using specially miniaturised componentry, has created a pen-sized digital microscope, which can be used on any tissue it contacts to produce high-resolution digital pathology images for cancer diagnosis and surgical margin detection in real-time. The aim of our technology development is for earlier diagnosis and subsequent treatment of cancerous tumours with expected associated improved patient outcomes.

To learn more about Optiscan, visit www.optiscan.com or follow us on [LinkedIn](#), [X](#) or [Instagram](#).

Disclaimer

All statements other than statements of historical fact included on this announcement including, without limitation, statements regarding future plans and objectives of Optiscan or any of the other parties referred to herein, are forward-looking statements. Forward-looking statements can be identified by words such as ‘anticipate’, ‘believe’, ‘could’, ‘estimate’, ‘expect’, ‘future’, ‘intend’, ‘may’, ‘opportunity’, ‘plan’, ‘potential’, ‘project’, ‘seek’, ‘will’ and other similar words that involve risks and uncertainties. These statements are based on an assessment of present economic and operating conditions, and on assumptions regarding future events and actions that are expected to take place. Such forward-looking statements are not guarantees of future performance and involve known and unknown risks, uncertainties, assumptions and other important factors, many of which are beyond the control of the Company, its directors and management of Optiscan that could cause actual results to differ from the results expressed or anticipated in these statements.